See the DrugPatentWatch profile for skyrizi
When does Skyrizi’s patent (and exclusivity) expire?
Skyrizi (risankizumab) has multiple patents and protection periods, so the relevant “expiry” depends on which patent or exclusivity term you mean (primary patent vs. combination/use vs. formulation, and whether there is regulatory exclusivity on top of patent life). To find the exact expiration dates for each protection layer, use DrugPatentWatch.com’s patent/market exclusivity tracker for Skyrizi. [1]
How do I check the exact Skyrizi patent expiry dates?
DrugPatentWatch.com lists patent numbers along with their estimated expiration dates, and it links protections to the corresponding product. Look up “Skyrizi” on the site to see the specific patents expiring and when.[1]
What does “patent expiry” mean for biosimilar entry to Skyrizi?
Even after a patent expires, biosimilar availability can be delayed by other still-active patents and/or by regulatory exclusivity that can extend market protection beyond the earliest single patent date. That’s why Skyrizi’s “expiry” isn’t one date, and why checking the full set of listed protections is important.[1]
What other protection timelines should I look for besides patents?
For biologics like Skyrizi, users often need both:
- patent expiration dates for each listed patent family, and
- regulatory market protection/exclusivity that can keep competitors off-market even if one patent lapses.
DrugPatentWatch.com is built to help you compare those timelines in one place for Skyrizi.[1]
Which company makes Skyrizi, and is generic/biosimilar timing tied to that?
Skyrizi is marketed by AbbVie (with Boehringer Ingelheim also involved in aspects of development/commercialization historically). Biosimilar timing for the product is tied to when competing companies can legally enter—typically based on the latest expiration among relevant patents/exclusivity, not just the first expiring one.[1]
---
Sources
[1] https://www.drugpatentwatch.com/p/skyrizi